Australia - English - Department of Health (Therapeutic Goods Administration)

medsurge pharma pty ltd - clonidine hydrochloride, quantity: 150 microgram/ml - injection, solution - excipient ingredients: sodium chloride; hydrochloric acid; water for injections - mz clonidine hcl injection is indicated for acute hypertensive crisis and as an alternative to oral therapy where the oral route of administration is inappropriate.

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - clonidine (unii: mn3l5rmn02) (clonidine - unii:mn3l5rmn02) - clonidine 0.1 mg in 1 d - clonidine transdermal system is indicated in the treatment of hypertension. it may be employed alone or concomitantly with other antihypertensive agents. clonidine transdermal system should not be used in patients with known hypersensitivity to clonidine or to any other component of the transdermal system.

United States - English - NLM (National Library of Medicine)

xgen pharmaceuticals djb, inc. - clonidine hydrochloride (unii: w76i6xxf06) (clonidine - unii:mn3l5rmn02) - clonidine hydrochloride 100 ug in 1 ml - clonidine hydrochloride injection is indicated in combination with opiates for the treatment of severe pain in cancer patients that is not adequately relieved by opioid analgesics alone. epidural clonidine is more likely to be effective in patients with neuropathic pain than somatic or visceral pain (see clinical trials ). the safety of this drug product has only been established in a highly selected group of cancer patients, and only after an adequate trial of opioid analgesia. other use is of unproven safety and is not recommended. in a rare patient, the potential benefits may outweigh the known risks (see warnings ). clonidine hydrochloride injection is contraindicated in patients with a history of sensitization or allergic reactions to clonidine. epidural administration is contraindicated in the presence of an injection site infection, in patients on anticoagulant therapy, and in those with a bleeding diathesis. administration of clonidine hydrochloride injection above the c4 dermatome is contraindicated since there are no adequate safety data to support such use (see warnings ).

Australia - English - Department of Health (Therapeutic Goods Administration)

medsurge pharma pty ltd - clonidine hydrochloride, quantity: 150 microgram/ml - injection, solution - excipient ingredients: sodium chloride; hydrochloric acid; water for injections - clonidine hci injection medsurge is indicated for acute hypertensive crisis and as an alternative to oral therapy where the oral route of administration is inappropriate.

United States - English - NLM (National Library of Medicine)

american health packaging - clonidine hydrochloride (unii: w76i6xxf06) (clonidine - unii:mn3l5rmn02) - clonidine hydrochloride 0.1 mg - clonidine hydrochloride extended-release tablets are indicated for the treatment of attention deficit hyperactivity disorder (adhd) as monotherapy and as adjunctive therapy to stimulant medications [see clinical studies ( 14)]. clonidine hydrochloride extended-release tablets are contraindicated in patients with a history of a hypersensitivity reaction to clonidine. reactions have included generalized rash, urticaria, and angioedema [see adverse reactions ( 6) ] . pregnancy category c: risk summary there are no adequate or well-controlled studies with clonidine hydrochloride extended-release tablets in pregnant women. in animal embryofetal studies, increased resorptions were seen in rats and mice administered oral clonidine hydrochloride from implantation through organogenesis at 10 and 5 times, respectively, the maximum recommended human dose (mrhd). no embryotoxic or teratogenic effects were seen in rabbits administered oral clonidine hydrochloride during organogenesis at doses up to 3 times the

United States - English - NLM (National Library of Medicine)

akorn - apraclonidine hydrochloride (unii: d2vw67n38h) (apraclonidine - unii:843cen85di) - apraclonidine 5 mg in 1 ml - apraclonidine ophthalmic solution, usp 0.5% as base is indicated for short-term adjunctive therapy in patients on maximally tolerated medical therapy who require additional iop reduction. patients on maximally tolerated medical therapy who are treated with apraclonidine ophthalmic solution, usp 0.5% as base to delay surgery should have frequent follow-up examinations and treatment should be discontinued if the intraocular pressure rises significantly. the addition of apraclonidine ophthalmic solution, usp 0.5% as base to patients already using two aqueous suppressing drugs (i.e., beta-blocker plus carbonic anhydrase inhibitor) as part of their maximally tolerated medical therapy may not provide additional benefit. this is because apraclonidine ophthalmic solution, usp 0.5% as base is an aqueous suppressing drug and the addition of a third aqueous suppressant may not significantly reduce iop. the iop lowering efficacy of apraclonidine ophthalmic solution, usp 0.5% as base diminishes over time in some patients.

United States - English - NLM (National Library of Medicine)

sandoz inc - apraclonidine hydrochloride (unii: d2vw67n38h) (apraclonidine - unii:843cen85di) - apraclonidine 5.75 mg in 1 ml - apraclonidine ophthalmic solution 0.5% is indicated for short-term adjunctive therapy, in patients on maximally tolerated medical therapy, who require additional iop reduction. patients on maximally tolerated medical therapy, who are treated with apraclonidine ophthalmic solution 0.5% to delay surgery, should have frequent follow-up examinations and treatment should be discontinued if the iop rises significantly. the addition of apraclonidine ophthalmic solution 0.5% to patients already using two aqueous suppressing drugs (i.e., beta-blocker plus carbonic anhydrase inhibitor) as part of their maximally tolerated medical therapy may not provide additional benefit. this is because apraclonidine ophthalmic solution 0.5% is an aqueous suppressing drug and the addition of a third aqueous suppressant may not significantly reduce iop. the iop lowering efficacy of apraclonidine ophthalmic solution 0.5% diminishes over time in some patients. this loss of effect, or tachyphylaxis, appears to be an individual occurrence

United States - English - NLM (National Library of Medicine)

pharmaforce, inc. - clonidine hydrochloride (unii: w76i6xxf06) (clonidine - unii:mn3l5rmn02) - clonidine hydrochloride 100 ug in 1 ml - clonidine hydrochloride is indicated in combination with opiates for the treatment of severe pain in cancer patients that is not adequately relieved by opioid analgesics alone. epidural clonidine is more likely to be effective in patients with neuropathic pain than somatic or visceral pain (see clinical pharmacology, clinical trials). the safety of this drug product has only been established in a highly selected group of cancer patients, and only after an adequate trial of opioid analgesia. other use is of unproven safety and is not recommended. in a rare patient, the potential benefits may outweigh the known risks (see warnings). clonidine hydrochloride is contraindicated in patients with a history of sensitization or allergic reactions to clonidine. epidural administration is contraindicated in the presence of an injection site infection, in patients on anticoagulant therapy, and in those with a bleeding diathesis. administration of clonidine hydrochloride above the c4 dermatome is contraindicated since the

United States - English - NLM (National Library of Medicine)

state of florida doh central pharmacy - clonidine hydrochloride (unii: w76i6xxf06) (clonidine - unii:mn3l5rmn02) - clonidine hydrochloride 0.1 mg - clonidine hydrochloride is indicated in the treatment of hypertension. clonidine hydrochloride may be employed alone or concomitantly with other antihypertensive agents. clonidine hydrochloride tablets should not be used in patients with known hypersensitivity to clonidine (see precautions).

United States - English - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, llc - clonidine hydrochloride (unii: w76i6xxf06) (clonidine - unii:mn3l5rmn02) - clonidine hydrochloride 0.3 mg - clonidine hydrochloride tablets, usp are indicated in the treatment of hypertension. clonidine hydrochloride tablets may be employed alone or concomitantly with other antihypertensive agents. clonidine hydrochloride tablets should not be used in patients with known hypersensitivity to clonidine (see precautions ).